Literature DB >> 17520763

Superselective neck dissection after chemoradiation: feasibility based on clinical and pathologic comparisons.

K Thomas Robbins1, Kerwin Shannon, Francisco Vieira.   

Abstract

OBJECTIVE: To determine whether superselective neck dissection (removal of 2 or less contiguous neck levels) is effective salvage surgery for patients with residual single-level adenopathy after concomitant intra-arterial cisplatin and radiotherapy.
DESIGN: Analysis of prospectively collected data.
SUBJECTS: The study group comprised 177 patients (239 heminecks) with N+ disease.
INTERVENTIONS: Intra-arterial treatment with cisplatin (150 mg/m2) on days 1, 8, 15, and 22 and radiation therapy (2 Gy/d) 5 times per week for 7 weeks. Comparisons were made between neck-level-specific disease at restaging and pathologic disease after neck dissection.
RESULTS: Tumor sites included oropharynx (n = 81), hypopharynx (39), larynx (n=27), oral cavity (n = 19), and other (n = 11). Response of nodal disease based on clinical evaluation was as follows: complete response, 89 patients (50%); partial response, 81 patients (46%); progressive disease, 4 patients (2%); and unevaluable, 3 patients (2%). Of the 89 patients whose necks were restaged as a partial response, 73 had clinical evidence of residual adenopathy involving only 1 neck level. Within this subset, 54 patients (57 heminecks) subsequently underwent a salvage neck dissection, for which comparisons were made between the restaging evidence of residual adenopathy and the pathologic findings that were specific for each neck level. Only 2 of the 54 patients had evidence of pathologic disease extending beyond the single neck level: one had disease in a contiguous neck level, and the other had disease in a noncontiguous level. The use of superselective neck dissection with removal of only 2 contiguous neck levels would have encompassed known disease in all but 1 patient.
CONCLUSION: Superselective neck dissection is feasible after this specific chemoradiation protocol has been administered to patients with persistent nodal disease that is confined to 1 level.

Entities:  

Mesh:

Year:  2007        PMID: 17520763     DOI: 10.1001/archotol.133.5.486

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  9 in total

1.  Radical neck dissection: is it still indicated?

Authors:  Marc Hamoir; Carl E Silver; Sandra Schmitz; Robert P Takes; Alessandra Rinaldo; Juan P Rodrigo; K Thomas Robbins; Karen T Pitman; Jesus E Medina; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-30       Impact factor: 2.503

2.  Neck dissection after chemoradiotherapy for oropharyngeal and hypopharyngeal cancer: the correlation between cervical lymph node metastasis and prognosis.

Authors:  Nobuhiro Hanai; Daisuke Kawakita; Taijiro Ozawa; Hitoshi Hirakawa; Takeshi Kodaira; Yasuhisa Hasegawa
Journal:  Int J Clin Oncol       Date:  2013-01-23       Impact factor: 3.402

Review 3.  Superselective neck dissection: rationale, indications, and results.

Authors:  Carlos Suárez; Juan P Rodrigo; K Thomas Robbins; Vinidh Paleri; Carl E Silver; Alessandra Rinaldo; Jesus E Medina; Marc Hamoir; Alvaro Sanabria; Vanni Mondin; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-16       Impact factor: 2.503

4.  Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome.

Authors:  Ian Ganly; Jennifer Bocker; Diane L Carlson; Salvatore D'Arpa; Maria Coleman; Nancy Lee; David G Pfister; Jatin P Shah; Snehal G Patel
Journal:  Head Neck       Date:  2010-11-04       Impact factor: 3.147

5.  Persistent lymph nodes after curative chemoradiotherapy for head and neck cancer: imaging predictors of response for decision-making.

Authors:  Alfredo Páez-Carpio; Santiago Medrano-Martorell; Joan Berenguer; Africa Muxí; Isabel Vilaseca; Izaskun Valduvieco; Paola Castillo; Neus Baste; F Xavier Avilés-Jurado; Juan José Grau; Laura Oleaga
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-10-01       Impact factor: 3.236

Review 6.  Efficacy of neck dissection in the management of isolated nodal recurrence after head and neck cancer treatment.

Authors:  Jimmy Yu-wai Chan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

7.  Neck dissection for oral squamous cell carcinoma: our experience and a review of the literature.

Authors:  Pooja Rani; Yogesh Bhardwaj; Praveen Kumar Dass; Manoj Gupta; Divye Malhotra; Narottam Kumar Ghezta
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2015-12-17

Review 8.  Current philosophy in the surgical management of neck metastases for head and neck squamous cell carcinoma.

Authors:  H Hakan Coskun; Jesus E Medina; K Thomas Robbins; Carl E Silver; Primož Strojan; Afshin Teymoortash; Phillip K Pellitteri; Juan P Rodrigo; Sandro J Stoeckli; Ashok R Shaha; Carlos Suárez; Dana M Hartl; Remco de Bree; Robert P Takes; Marc Hamoir; Karen T Pitman; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2014-06-30       Impact factor: 3.147

9.  Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term results.

Authors:  Giulia Bertino; Antonio Occhini; Carlo Emilio Falco; Camillo Porta; Franco Corbella; Sara Colombo; Vittoria Balcet; Patrizia Morbini; Federico Zappoli; Andrea Azzaretti; Giuseppe Rodolico; Carmine Tinelli; Marco Benazzo
Journal:  BMC Cancer       Date:  2009-09-04       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.